United States-based Novadoz Pharmaceuticals announced on Wednesday that its corporate group entity, MSN Pharmaceuticals, has received approval from United States Food and Drug Administration (FDA) audit with zero observations for its new, 200,000 sq. ft. manufacturing facility in Piscataway, New Jersey.
The new facility is to produce high quality, generic pharmaceuticals to include both oral solids and liquids. It will include a modern lab and executive offices for both MSN Pharmaceuticals and Novadoz Pharmaceuticals.
The company has also received approval for generic Tiagabine (AB rated to Gabitril). Tiagabine 2mg, 4mg, 12mg & 16mg tablets are offered in bottles of 30. The product is indicated as adjunctive treatment for partial seizures in patients age 12-years and older.
Indivior reaches settlement in patent infringement case with Dr. Reddy's Laboratories
Kazia Therapeutics' paxalisib receives Orphan Drug Designation from FDAQ
Dr. Reddy's Laboratories Launches Pemetrexed for Injection USP, in the US Market
Accord Healthcare introduces Pemetrexed Lyo. Injection to range of chemotherapy drugs
Astellas receives unfavourable decision in LEXISCAN(R) 0.4mg/mL US patent trial
Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows